MX2022016263A - Derivados de ciclobutil-urea. - Google Patents

Derivados de ciclobutil-urea.

Info

Publication number
MX2022016263A
MX2022016263A MX2022016263A MX2022016263A MX2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A
Authority
MX
Mexico
Prior art keywords
sup
cyclobutyl
urea derivatives
compounds
formula
Prior art date
Application number
MX2022016263A
Other languages
English (en)
Inventor
Romain Siegrist
Jens- Uwe PETERS
Jean- Philippe SURIVET
Olivier Bezencon
Caroline Deymier
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2022016263A publication Critical patent/MX2022016263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a compuestos de la Fórmula (I) (ver Fórmula) Fórmula (I) donde X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5 y R6 son como se describen en la descripción; a su preparación, a sus sales farmacéuticamente aceptables, a las composiciones farmacéuticas que contienen uno o más compuestos de la Fórmula (I) y al uso de tales compuestos como medicamentos, especialmente como abridores de KV7.
MX2022016263A 2020-06-25 2021-06-24 Derivados de ciclobutil-urea. MX2022016263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020067903 2020-06-25
PCT/EP2021/067288 WO2021260090A1 (en) 2020-06-25 2021-06-24 Cyclobutyl-urea derivatives

Publications (1)

Publication Number Publication Date
MX2022016263A true MX2022016263A (es) 2023-02-09

Family

ID=76624055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016263A MX2022016263A (es) 2020-06-25 2021-06-24 Derivados de ciclobutil-urea.

Country Status (11)

Country Link
US (1) US20230303486A1 (es)
EP (1) EP4172140A1 (es)
JP (1) JP2023531500A (es)
KR (1) KR20230029813A (es)
CN (1) CN115702141A (es)
AR (1) AR122739A1 (es)
AU (1) AU2021295422A1 (es)
CA (1) CA3183298A1 (es)
MX (1) MX2022016263A (es)
TW (1) TW202216660A (es)
WO (1) WO2021260090A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20242216A1 (es) * 2021-11-19 2024-11-19 Icagen Llc Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
EP4479377A1 (en) * 2022-02-15 2024-12-25 Icagen, LLC New bicyclopentane derivatives
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3
WO2025252599A1 (en) * 2024-06-04 2025-12-11 Angelini Pharma S.P.A. Activating compounds of potassium channels kv7.2/kv7.3
WO2025252600A1 (en) * 2024-06-04 2025-12-11 Angelini Pharma S.P.A. Activating compounds of potassium channels kv7.2/kv7.3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2712163C2 (ru) * 2014-10-24 2020-01-24 Оно Фармасьютикал Ко., Лтд. Активатор kcnq2-5 каналов
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
MA51881B1 (fr) 2018-02-20 2023-08-31 H Lundbeck As Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
CN113692304B (zh) 2019-02-06 2025-03-18 礼来公司 作为kcnq增强剂的1-((2-(2,2,2-三氟乙氧基)吡啶-4-基)甲基)脲衍生物
NZ784711A (en) * 2019-07-30 2025-11-28 Taisho Pharmaceutical Co Ltd Urea compound for antagonizing lpa1 receptor

Also Published As

Publication number Publication date
EP4172140A1 (en) 2023-05-03
AU2021295422A1 (en) 2023-02-23
WO2021260090A1 (en) 2021-12-30
TW202216660A (zh) 2022-05-01
AR122739A1 (es) 2022-10-05
CA3183298A1 (en) 2021-12-30
KR20230029813A (ko) 2023-03-03
CN115702141A (zh) 2023-02-14
US20230303486A1 (en) 2023-09-28
JP2023531500A (ja) 2023-07-24

Similar Documents

Publication Publication Date Title
MX2022016263A (es) Derivados de ciclobutil-urea.
MX2024006681A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
AP1739A (en) Azaindoles
UA94901C2 (ru) Антибактериальные производные пиперидина
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2022015886A (es) Derivados de amidopirimidona.
BR0212829A (pt) Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
BG103969A (en) C-4"-substituted macrolide derivatives
ATE316083T1 (de) Adamantanderivate
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
ATE386725T1 (de) Heterocyclylverbindungen
SE9901573D0 (sv) New compounds
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
MY147373A (en) Piperazine derivatives as antimalarial agents
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
MX2021015727A (es) Derivados de piridin-3-ilo.